[HTML][HTML] Advances in genetic variation in metabolism-related fatty liver disease
F Shi, M Zhao, S Zheng, L Zheng, H Wang - Frontiers in Genetics, 2023 - frontiersin.org
Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver
disease in the world. Its pathogenesis is influenced by both environmental and genetic …
disease in the world. Its pathogenesis is influenced by both environmental and genetic …
[HTML][HTML] Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Y Wang, JS Fleishman, T Li, Y Li, Z Ren… - Frontiers in …, 2024 - frontiersin.org
In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …
[HTML][HTML] Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
JM Herranz, A López-Pascual… - Journal of physiology …, 2023 - Springer
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition with a complex
etiology. Its incidence is increasing globally in parallel with the obesity epidemic, and it is …
etiology. Its incidence is increasing globally in parallel with the obesity epidemic, and it is …
[HTML][HTML] Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
B Filipovic, M Marjanovic-Haljilji, D Mijac… - Current Issues in …, 2023 - mdpi.com
Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than
90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial …
90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial …
Clinical classification of obesity and implications for metabolic dysfunction-associated fatty liver disease and treatment
Y Ding, Q Deng, M Yang, H Niu, Z Wang… - … Syndrome and Obesity, 2023 - Taylor & Francis
Obesity, and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached
epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically …
epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically …
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
P Portincasa, M Khalil, L Mahdi, V Perniola… - International Journal of …, 2024 - mdpi.com
The epidemiological burden of liver steatosis associated with metabolic diseases is
continuously growing worldwide and in all age classes. This condition generates possible …
continuously growing worldwide and in all age classes. This condition generates possible …
Molecular pathogenesis of metabolic dysfunction‐associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis
T Saito, M Tsuchishima, M Tsutsumi… - Journal of Cellular and …, 2024 - Wiley Online Library
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is characterized by
intense deposition of fat globules in the hepatic parenchyma that could potentially progress …
intense deposition of fat globules in the hepatic parenchyma that could potentially progress …
[HTML][HTML] Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 …
Metabolic-associated fatty liver disease (MAFLD), formerly referred to as non-alcoholic fatty
liver disease (NAFLD), is a common liver disease characterized by an abnormal buildup of …
liver disease (NAFLD), is a common liver disease characterized by an abnormal buildup of …
[HTML][HTML] Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients' prognosis and pharmacotherapy: MASLD: new pathogenic …
MG Fernández-Barrena, MA Avila - Journal of physiology and …, 2023 - Springer
Excessive hepatic fat accumulation in the absence of high alcohol consumption, up to date
referred to as nonalcoholic fatty liver disease (NAFLD), has emerged in recent years as one …
referred to as nonalcoholic fatty liver disease (NAFLD), has emerged in recent years as one …
Resmetirom: First Approval
SJ Keam - Drugs, 2024 - Springer
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being
developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of …
developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of …